How will Curatis Holding AG’s CHF 1.2 million convertible instrument work?

The strategic Swiss investor will subscribe for a convertible instrument that can be converted into shares of Curatis Holding AG. The shares are expected to be delivered from Curatis’ conditional capital.

What conditions apply to Curatis Holding AG’s private placement?

Curatis Holding AG said the transaction is expected to close within the next few days, subject to customary conditions. The announcement does not provide further details of those conditions.

When did Curatis Holding AG announce the private placement?

Curatis Holding AG made the announcement on 21 November 2025 in Liestal, Switzerland.

What will Curatis Holding AG use the private placement proceeds for?

Curatis Holding AG said the proceeds will first and foremost allow it to accelerate development of its late-stage clinical lead product candidate, corticorelin.

At what conditions was Curatis Holding AG’s convertible instrument issued?

Curatis Holding AG said the convertible instrument was issued at prevailing market conditions.

What does Curatis Holding AG do?

Curatis Holding AG specialises in the final development and commercialisation of drugs for rare and very rare diseases. The company said it has a sales portfolio of more than 40 products and a pipeline of orphan drug products and specialist products.

Where are Curatis Holding AG’s shares listed and what ticker symbols does it use?

Curatis Holding AG is identified in the announcement as listed on SIX under the ticker symbol SIX: CURN, and its company description gives CURN.SW as its ticker symbol.

What is Curatis Holding AG’s lead clinical product candidate?

Curatis Holding AG identified corticorelin as its late-stage clinical lead product candidate. The company said the private placement proceeds will be used first and foremost to accelerate its development.

What happens next for Curatis Holding AG’s private placement?

Curatis Holding AG said the transaction is expected to close within the next few days, subject to customary conditions. The investor is expected to subscribe for the convertible instrument, with the resulting shares expected to be delivered from Curatis’ conditional capital.

Home
News Intelligence
Curatis Holding AG
Curatis agrees CHF 1.2 million convertible placement, subject to conditions

Back to all Curatis Holding AG press releases

Curatis Holding AG

SIX:CURN

Curatis agrees CHF 1.2 million convertible placement, subject to conditions

Published Friday, 21 November 2025, 06:00 AM

Get alerts

Plain English summaries when Curatis Holding AG announces news.

At a glance

Company: Curatis Holding AG
Listings: SIX:CURN
Announcement type: Financing
Published: Friday, 21 November 2025, 06:00 AM
Source announcement: eqs-news.com

Key figures
Measure	Figure
Private placement of a convertible instrument	CHF 1.2 million

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Curatis Holding AG (SIX: CURN; CURN.SW) announced a definitive agreement for a private placement.

The placement involves a CHF 1.2 million convertible instrument with a strategic Swiss investor.
The shares are expected to be delivered from Curatis’ conditional capital.
Curatis expects the transaction to close within the next few days, subject to customary conditions.

The company said proceeds will accelerate development of late stage clinical lead product candidate corticorelin.

Investor FAQs

Curatis Holding AG announced that it had entered into a definitive agreement for a CHF 1.2 million private placement of a convertible instrument with a strategic Swiss investor. The agreement remains subject to customary conditions.

Source announcement

Company: Curatis Holding AG
Title: Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
Published: Friday, 21 November 2025, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…